Skip to main content
TLSA
NASDAQ Life Sciences

Phase 2a Win: Intranasal Foralumab Cuts Neuroinflammation in Progressive MS

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.869
Mkt Cap
$102.647M
52W Low
$0.762
52W High
$1.96
52W Position info
14% above low
Off High info
56% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

TLSA is trading near its 52-week low of $0.762 (14% above the low).

Summary

Tiziana's Phase 2a INFORM-MS trial hit both primary endpoints in non-active secondary progressive MS, a disease with no FDA-approved therapy. The 50 μg nasal foralumab arm showed a statistically significant reduction in microglial activation on TSPO PET (p=0.0168), and both doses were safe and well tolerated with no discontinuations or drug-related serious adverse events across 48 patients. Fatigue scores fell 6.17 points at 50 μg and 7.18 at 100 μg versus 3.12 on placebo, though the study was not powered for clinical endpoints and EDSS showed no change over 12 weeks. The 100 μg arm did not reach significance on the PET endpoint, so the imaging win rests on the smaller 50 μg cohort. This lands three weeks after the 6-K confirming last patient last visit, and it matters most because the company reported a $12.4M first-half loss with just $3.9M of cash and going-concern doubt — a positive registrational-path story is the main lever for financing. Next step is an FDA meeting on the path forward in na-SPMS, with full data slated for a scientific congress.

At the time of this announcement, TLSA was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $102.6M. The 52-week trading range was $0.76 to $1.96. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TLSA - Latest Insights

TLSA
Nov 05, 2026, 2:26 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.6249
Real-time Price: $0.690 info
Change: +$0.0651 (+10%) info
Market Cap: $86.686M info
TLSA
Nov 02, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $0.890
Real-time Price: $0.690 info
Change: -$0.200 (-22%) info
Market Cap: $86.686M info
TLSA
Oct 16, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.690 info
Change: -$0.360 (-34%) info
Market Cap: $86.686M info
TLSA
Oct 16, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.690 info
Change: -$0.380 (-36%) info
Market Cap: $86.686M info
TLSA
Sep 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.690 info
Change: -$0.310 (-31%) info
Market Cap: $86.686M info